These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27312514)

  • 1. An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer.
    Wang L; Wu YL; Lu S; Deng L; Ahn MJ; Hsu FM; Iscoe N; Hossain A; Puri T; Zhang P; Orlando M
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):380-387. PubMed ID: 27312514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Senan S; Brade A; Wang LH; Vansteenkiste J; Dakhil S; Biesma B; Martinez Aguillo M; Aerts J; Govindan R; Rubio-Viqueira B; Lewanski C; Gandara D; Choy H; Mok T; Hossain A; Iscoe N; Treat J; Koustenis A; San Antonio B; Chouaki N; Vokes E
    J Clin Oncol; 2016 Mar; 34(9):953-62. PubMed ID: 26811519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology.
    Vokes EE; Senan S; Treat JA; Iscoe NA
    Clin Lung Cancer; 2009 May; 10(3):193-8. PubMed ID: 19443340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial.
    Park CK; Oh IJ; Kim KS; Choi YD; Jang TW; Kim YS; Lee KH; Shin KC; Jung CY; Yang SH; Ryu JS; Jang SH; Yoo SS; Yong SJ; Lee KY; In KH; Lee MK; Kim YC
    Clin Lung Cancer; 2017 Jul; 18(4):e289-e296. PubMed ID: 28185792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC.
    Vokes EE; Govindan R; Iscoe N; Hossain AM; San Antonio B; Chouaki N; Koczywas M; Senan S
    J Thorac Oncol; 2018 Aug; 13(8):1183-1188. PubMed ID: 29733908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy in non-small cell lung cancer: opportunities for advancement.
    Akhtari M; Bernicker EH; Teh BS
    Chin J Cancer; 2016 Jun; 35(1):56. PubMed ID: 27339154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
    Niho S; Kubota K; Nihei K; Sekine I; Sumi M; Sekiguchi R; Funai J; Enatsu S; Ohe Y; Tamura T
    Clin Lung Cancer; 2013 Jan; 14(1):62-9. PubMed ID: 22633219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
    Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
    Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
    Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial.
    Lee DH; Lee JS; Wang J; Hsia TC; Wang X; Kim J; Orlando M
    Cancer Res Treat; 2015 Oct; 47(4):616-29. PubMed ID: 25672577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
    Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
    Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
    Wu YL; Lu S; Cheng Y; Zhou C; Wang M; Qin S; Lu Y; Zhang Y; Zhu Y; Song X; Wang X; Barraclough H; Zhang X; Chi H; Orlando M
    Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Lu S; Cheng Y; Zhou CC; Wang J; Chih-Hsin Yang J; Zhang PH; Zhang XQ; Wang X; Orlando M; Wu YL
    Clin Lung Cancer; 2016 Sep; 17(5):e103-e112. PubMed ID: 27236385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer.
    Brade A; MacRae R; Laurie SA; Bezjak A; Burkes R; Chu Q; Goffin JR; Cho J; Hope A; Sun A; Leighl N; Capobianco S; Feld R; Mahalingam E; Hossain A; Iscoe N; Shepherd FA
    Clin Lung Cancer; 2016 Mar; 17(2):133-41. PubMed ID: 26872764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
    Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL
    Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Novello S; Scagliotti G; de Castro G; Kiyik M; Kowalyszyn R; Deppermann KM; Arriola E; Bosquee L; Novosiadly RD; Nguyen TS; Forest A; Tang S; Kambhampati SRP; Cosaert J; Reck M
    J Thorac Oncol; 2017 Feb; 12(2):383-389. PubMed ID: 27464970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
    Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
    Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
    J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.